Mohammad A. Razaq

Hematology
4300 W Memorial Rd
Oklahoma City, OK 73120

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

Journal: Cancer
Published: July 23, 2024

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 04, 2023

Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.

Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.

Journal: Head & neck
Published: March 03, 2021

Merkel cell carcinoma: treatment and outcomes over a 10-year period at a high-volume academic center.

Merkel cell carcinoma: treatment and outcomes over a 10-year period at a high-volume academic center.

Journal: International journal of dermatology
Published: January 29, 2021

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Journal: The Lancet. Oncology
Published: August 11, 2020

Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.

Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.

Journal: Cancer
Published: April 01, 2020

Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs.

Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs.

Journal: Cancer letters
Published: March 01, 2020

Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303.

Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303.

Journal: Journal of palliative medicine
Published: February 08, 2020

Progress in extracellular vesicle biology and their application in cancer medicine.

Progress in extracellular vesicle biology and their application in cancer medicine.

Journal: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Published: November 19, 2019

Exosomes as Theranostics for Lung Cancer.

Exosomes as Theranostics for Lung Cancer.

Journal: Advances in cancer research
Published: June 27, 2018

Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.

Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.

Journal: American journal of therapeutics
Published: March 21, 2018

Hypersensitivity to Cetuximab After Geographic Relocation.

Hypersensitivity to Cetuximab After Geographic Relocation.

Journal: American journal of therapeutics
Published: January 09, 2018
Showing 1-12 of 16

Last Updated: 09/26/2026